SCHEDULE 13D/A: Key Insiders Drastically Reduce Stake in IMPACT BIOMEDICAL INC., Selling Millions of Shares

Heng Fai Ambrose Chan and his affiliated entities, Alset Inc., Alset International Limited, and Global Biomedical Pte. Ltd., have significantly reduced their beneficial ownership in IMPACT BIOMEDICAL INC. through a series of share sales in late March and early April 2025.

Summary

• Heng Fai Ambrose Chan, Alset Inc., and Alset International Limited collectively beneficially own 351,555 shares of IMPACT BIOMEDICAL INC. common stock, representing 2.9% of the outstanding shares as of April 4, 2025.
• Global Biomedical Pte. Ltd. no longer holds any shares in IMPACT BIOMEDICAL INC.
• Alset International Limited sold a total of 502,349 shares on April 2, 2025, at weighted average prices ranging from $0.581 to $0.674.
• Alset Inc. sold a total of 734,058 shares on April 2 and April 3, 2025, at weighted average prices of $0.583 and $0.579, respectively.
• Global Biomedical Pte. Ltd. sold a total of 453,286 shares on April 3 and April 4, 2025, at weighted average prices of $0.779 and $0.96, respectively.
• Prior to these sales, Alset International Limited also sold 300,000 shares on March 31, 2025, at a weighted average price of $1.028, and 400,000 shares on April 1, 2025, at $0.9816.
• Alset Inc. sold an additional 650,000 shares at $1.447 and 1,176,918 shares at $1.08 on April 1, 2025.
• The total number of shares sold by these reporting persons between March 31, 2025, and April 4, 2025, exceeds 4.2 million shares.

Sentiment

Score: 2

Explanation: The sentiment is negative due to the extensive insider selling by key affiliated entities, which typically signals a lack of confidence in the company's future prospects from those with the most insight.

Negatives

• Significant reduction in beneficial ownership by key insiders and affiliated entities, indicating a potential lack of confidence or a strategic divestment.
• Large volume of shares sold across multiple transactions over a short period (late March to early April 2025).
• The sales occurred at varying price points, some significantly lower than previous transactions, suggesting a willingness to sell even at declining prices.

Risks

• The substantial insider selling could signal a negative outlook on the company's future performance by those with intimate knowledge.
• Increased selling pressure on the stock due to the large volume of shares offloaded by major shareholders.
• Potential loss of investor confidence due to the divestment by key affiliated entities.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the Issuer's future operations or financial performance. It solely reports changes in beneficial ownership.

Industry Context

This filing is specific to changes in beneficial ownership by a major shareholder group and does not provide information directly related to broader industry trends or competitive landscape for IMPACT BIOMEDICAL INC. However, significant insider selling can be a negative signal for the company within its industry, as it may suggest a lack of confidence from key stakeholders.

Corporate Governance

Related Party Transactions

• Heng Fai Chan, Alset Inc., Alset International Limited, and Global Biomedical Pte. Ltd. are related parties, with Mr. Chan controlling Alset Inc., which is the majority shareholder of Alset International Limited, and Global Biomedical Pte. Ltd. being a wholly-owned subsidiary of Alset International Limited. The reported share sales are transactions between these related parties and the market.

Stakeholder Impact

• Shareholders: The significant insider selling could lead to a decrease in share price due to negative market sentiment and increased supply of shares.
• Investors: Potential loss of confidence in the company's future, as key insiders are divesting their holdings.
• Management: While the selling parties are related to management, the divestment could put pressure on the Issuer's management to demonstrate value and stability.

Next Steps

• The reporting persons undertake to provide full information regarding the number of shares and prices at which transactions were effected upon request of the SEC staff, the Issuer, or a security holder of the Issuer.

Key Dates

Recommendation

Keywords

IMPACT BIOMEDICAL INC., Schedule 13D/A, Insider Selling, Share Sales, Beneficial Ownership, Heng Fai Ambrose Chan, Alset Inc., Alset International Limited, Global Biomedical Pte. Ltd., SEC Filing, Common Stock